预防性护理策略减少大手术后中重度急性肾损伤:BigpAK-2多国随机临床试验
BigpAK-2为欧洲34家医院开展的多中心随机临床试验,纳入≥18岁、经预设临床危险因素和肾小管应激生物标志物识别为AKI高风险的大手术患者,随机接受常规护理或按KDIGO指南推荐的预防性护理策略(先进血流动力学监测、优化容量与血流动力学、避免肾毒药物和造影剂、预防高血糖)。主要终点为术后72小时内中重度AKI,干预组84/589(14.4%)vs 对照组131/591(22.3%),OR 0.57(95%CI 0.40-0.79,P=0.0002),NNT 12(7-33),不良事件无差异。
要点
- 大手术高AKI风险成人中,预防性护理策略使术后72小时内中重度AKI从22.3%降至14.4%(OR 0.57,95%CI 0.40-0.79,P=0.0002),NNT 12(7-33)。
- 预防策略包括先进血流动力学监测、优化容量状态与血流动力学、避免肾毒药物和造影剂、预防高血糖,按KDIGO指南推荐实施。
- 两组不良事件无差异,最常见为心房颤动(干预组8.8% vs 对照组9.7%)、血流动力学相关心律失常(7.2% vs 8.6%)、显著出血(6.0% vs 5.3%)、非计划重返手术室(5.1% vs 6.5%)。
- 高风险患者通过预设临床危险因素联合肾小管应激生物标志物识别,7873例筛查中1180例(15.0%)被随机分配。
适用人群与场景
- ≥18岁接受大手术、经预设临床危险因素和肾小管应激生物标志物识别为AKI高风险的患者,来自欧洲34家医院。
诊断标准与关键阈值
- AKI高风险由预设临床危险因素和肾小管应激生物标志物联合识别。
- 主要终点为术后72小时内发生中重度AKI。
处置流程与药物剂量
- 预防性护理策略按肾脏疾病改善全球结局(KDIGO)指南推荐实施:先进血流动力学监测、优化容量状态与血流动力学、避免肾毒药物和造影剂、预防高血糖。
研究设计与关键结果
- 多中心随机临床试验,欧洲34家医院,2020年11月25日至2024年6月21日筛查7873例,随机分配1180例(15.0%),干预组589例(49.9%),对照组591例(50.1%)。
- 主要终点可分析1176例,术后72小时内中重度AKI干预组84例(14.4%)vs 对照组131例(22.3%),OR 0.57(95%CI 0.40-0.79,P=0.0002),NNT 12(7-33)。
- 不良事件无差异:心房颤动干预组50例(8.8%)vs 对照组56例(9.7%);血流动力学相关心律失常41例(7.2%)vs 50例(8.6%);显著出血或出血事件34例(6.0%)vs 31例(5.3%);非计划重返手术室29例(5.1%)vs 38例(6.5%)。
证据类型、等级与局限
- 证据类型:多中心随机临床试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对经临床危险因素和肾小管应激生物标志物识别为AKI高风险的大手术成人,作者认为由支持性措施和避免肾毒物组成的预防性护理策略可显著减少术后72小时内中重度AKI且不增加不良事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) is a common and important complication of major surgery, yet recommended preventive care is rarely administered. We used urinary biomarkers to identify patients at high risk of AKI and implemented a preventive care strategy to reduce AKI within 72 h after major surgery.
METHODS: BigpAK-2 was a multicentre randomised clinical trial done in 34 hospitals in Europe. Patients (aged ≥18 years) undergoing major surgery at high risk for AKI identified by predefined clinical risk factors and tubular stress biomarkers were randomly assigned to usual care or a preventive care strategy as per recommendations by the Kidney Disease Improving Global Outcome guidelines: advanced hemodynamic monitoring, optimisation of volume status and haemodynamics, avoidance of nephrotoxic drugs and radiocontrast agents, and prevention of hyperglycaemia. The primary outcome was the occurrence of moderate or severe AKI within 72 h after surgery, assessed in the intention-to-treat population. Safety was assessed by comparing rates of adverse events between groups. This trial is registered with ClinicalTrials.gov, NCT04647396.
FINDINGS: From Nov 25, 2020, to June 21, 2024, 7873 patients were screened and 1180 (15·0%) were randomly assigned (589 [49·9%] to the intervention group and 591 [50·1%] to the control group). Among the 1176 patients available for the primary endpoint analysis, moderate or severe AKI occurred in 84 (14·4%) patients in the intervention group and in 131 (22·3%) patients in the control group (odds ratio 0·57 [95% CI 0·40-0·79; p=0·0002; number needed to treat 12 [7-33]). There were no differences in adverse events. The most common adverse events were atrial fibrillation (50 [8·8%] in the intervention group vs 56 (9·7%) in the control group), hemodynamically relevant arrhythmias (41 [7·2%] in the intervention group vs 50 [8·6%] in the control group), significant bleeding or haemorrhage (34 [6·0%] in the intervention group vs 31 [5·3%] in the control group), and unplanned return to the operating room (29 [5·1%] in the intervention vs 38 [6·5%] in the control group).
INTERPRETATION: Among adults at high risk for AKI undergoing major surgery, a preventive care strategy consisting of supportive measures and avoidance of nephrotoxins significantly reduced the occurrence of moderate or severe AKI without increasing adverse events.
FUNDING: BioMérieux.
参考来源
- Zarbock A, Ostermann M, Forni L, et al. A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial. Lancet. 2025. PMID: 41242333. doi:10.1016/S0140-6736(25)01717-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。